- Home
- SNSE vs KPRX Comparison
SNSE vs KPRX Comparison
Compare SNSE & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- KPRX
- Stock Information
- Founded
- SNSE 2005
- KPRX 1998
- Country
- SNSE United States
- KPRX United States
- Employees
- SNSE N/A
- KPRX N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SNSE Health Care
- KPRX Health Care
- Exchange
- SNSE Nasdaq
- KPRX Nasdaq
- Market Cap
- SNSE 11.2M
- KPRX 9.2M
- IPO Year
- SNSE 2021
- KPRX N/A
- Fundamental
- Price
- SNSE $11.13
- KPRX $2.78
- Analyst Decision
- SNSE Strong Buy
- KPRX Strong Buy
- Analyst Count
- SNSE 4
- KPRX 1
- Target Price
- SNSE $72.50
- KPRX $10.00
- AVG Volume (30 Days)
- SNSE 3.5K
- KPRX 35.2K
- Earning Date
- SNSE 11-13-2025
- KPRX 11-07-2025
- Dividend Yield
- SNSE N/A
- KPRX N/A
- EPS Growth
- SNSE N/A
- KPRX N/A
- EPS
- SNSE N/A
- KPRX N/A
- Revenue
- SNSE N/A
- KPRX N/A
- Revenue This Year
- SNSE N/A
- KPRX N/A
- Revenue Next Year
- SNSE N/A
- KPRX N/A
- P/E Ratio
- SNSE N/A
- KPRX N/A
- Revenue Growth
- SNSE N/A
- KPRX N/A
- 52 Week Low
- SNSE $5.00
- KPRX $2.25
- 52 Week High
- SNSE $17.40
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SNSE 71.14
- KPRX 55.83
- Support Level
- SNSE $9.35
- KPRX $2.67
- Resistance Level
- SNSE $10.00
- KPRX $2.89
- Average True Range (ATR)
- SNSE 0.51
- KPRX 0.11
- MACD
- SNSE 0.09
- KPRX 0.02
- Stochastic Oscillator
- SNSE 94.27
- KPRX 72.97
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.